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Abstract
Background—ST2 is involved in cardioprotective signaling in the myocardium and has been
identified as a potentially promising biomarker in HF. We evaluated ST2 levels and their
association with functional capacity and long-term clinical outcomes in a cohort of ambulatory
heart failure (HF) patients enrolled in the HF-ACTION study—a multicenter, randomized study of
exercise training in HF.
Methods and Results—HF-ACTION randomized 2331 patients with left ventricular ejection
fraction <0.35 and New York Heart Association class II–IV HF to either exercise training or usual
care. ST2 was analyzed in a subset of 910 patients with evaluable plasma samples. Correlations
and Cox models were used to assess the relationship among ST2, functional capacity, and long-
term outcomes.
The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6–31.8). ST2 was
modestly associated with measures of functional capacity. In univariable analysis, ST2 was
significantly associated with death or hospitalization (hazard ratio [HR], 1.48; p<0.0001),
cardiovascular death or HF hospitalization (HR, 2.14; p<0.0001), and all-cause mortality (HR,
2.33; p<0.0001)(all HRs for log-base2 ng/mL). In multivariable models, ST2 remained
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independently associated with outcomes after adjustment for clinical variables and amino-terminal
pro–B-type natriuretic peptide. However, ST2 did not add significantly to reclassification of risk
as assessed by changes in the C statistic, net reclassification improvement, and integrated
discrimination improvement.
Conclusions—ST2 was modestly associated with functional capacity and was significantly
associated with outcomes in a well-treated cohort of ambulatory HF patients, although it did not
significantly affect reclassification of risk.
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Introduction
Chronic heart failure is a major and growing public health issue, affecting more than 5
million people in the United States. Although there has been substantial progress in heart
failure therapy, overall prognosis remains poor, with 5-year mortality approaching 50% in
symptomatic patients1, 2. At the same time, the available treatment options have proliferated
and include many expensive and complex treatments such as cardiac resynchronization
therapy, left ventricular assist devices, and invasive hemodynamic monitors. Risk
stratification is therefore increasingly critical in order to apply costly and invasive therapies
to those patients most likely to benefit.
Biomarkers, in particular the natriuretic peptides, play an increasingly important role in the
risk stratification of heart failure patients3. A variety of biomarkers have emerged as
potentially useful clinical tools for heart failure, including ST24, galectin-35, growth-
differentiation factor 156, copeptin7, and midregional pro-hormone adrenomedullin8 among
many others. There remains a need to validate these newer biomarkers in diverse
populations with careful covariate adjustment in order to clarify their role in heart failure
management.
ST2 has been identified as the ligand for interleukin-33 (IL-33) and exists in both a trans-
membrane and soluble form. IL-33/ST2 signaling in the myocardium appears to be a
cardioprotective mechanism that limits hypertrophy and myocardial fibrosis9. Circulating
ST2 appears to function as a “decoy receptor,” modulating the effects of excessive IL-33
signaling10. The soluble form of ST2 has recently been identified as a promising biomarker
in patients with both acute coronary syndromes11 and heart failure4, 12. Accordingly, we
sought to evaluate how circulating ST2 levels are associated with other measures of heart
failure status and with long-term clinical outcomes in a cohort of ambulatory heart failure
patients enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of
Exercise Training(HF-ACTION) study—a large, multicenter, randomized study of exercise
training in heart failure.
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The primary results, design and rationale of the HF-ACTION study have been previously
published13, 14. Briefly, HF-ACTION (ClinicalTrials.gov identifier: NCT00047437) was a
randomized clinical study evaluating the effects of exercise training vs. usual care on long-
term morbidity and mortality in patients with chronic heart failure due to left ventricular
systolic dysfunction (New York Heart Association [NYHA] class II–IV, left ventricular
ejection fraction [LVEF]<0.35). The primary endpoint of HF-ACTION was a composite of
all-cause mortality and all-cause hospitalization. Randomization to exercise training in the
HF-ACTION study was associated with modest reductions in the primary endpoint and
other cardiovascular endpoints. An independent clinical events committee adjudicated all
deaths and first cardiovascular hospitalizations. HF-ACTION was approved by local
institutional review boards, and all enrolled patients provided written informed consent.
Biomarker assays
A subset of patients enrolled in the HF-ACTION study who agreed to participate in the
biomarker substudy underwent plasma collection at baseline, 3 months, and 12 months.
Baseline blood samples were obtained on the same day as baseline cardiopulmonary
exercise (CPX) testing but prior to exercise. Samples were collected via peripheral vein into
EDTA-containing tubes, centrifuged immediately, and then stored at −70°C for subsequent
analysis. Soluble ST2 levels were assessed on baseline samples using a highly sensitive
sandwich monoclonal immunoassay (Presage® ST2 Assay, Critical Diagnostics, New York,
NY), with a lower limit of detection of 2 ng/mL, an upper limit of detection of 200 ng/mL,
an intra-assay coefficient of variation <2.5%, and an interassay coefficient of variation of
<4.6%15. Amino-terminal pro–B-type natriuretic peptide (NT-proBNP) was assessed at a
central core lab using a clinically available assay (Roche Elecys®, Roche Diagnostics,
Indianapolis, IN). The core laboratories were blinded to all clinical data.
Statistical analysis
Baseline characteristics were described using medians and interquartile ranges or
proportions. The outcome variables of interest were 1) time to all-cause hospitalization or
all-cause mortality (the primary outcome of the HF-ACTION study), 2) time to
cardiovascular death or heart failure hospitalization, 3) time to all-cause mortality, and 4)
change in peak VO2 from baseline to 3 months.
ST2 was a continuous variable in all models but was log transformed for analysis because it
was not normally distributed. Hazard ratios (HRs) were calculated for the log base 2, such
that the reported HR represented the risk per doubling of ST2. Although our primary
analysis was focused on ST2 as a continuous variable, for descriptive purposes we also
examined ST2 as a dichotomous variable above and below the clinical cutpoint of 35 ng/mL
(based on receiver operating characteristic curve analysis and U.S. Food and Drug
Administration labeling)4.
The relationships among ST2 levels and other baseline variables of interest were analyzed
using simple correlations. For the clinical outcomes of interest, we analyzed the
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relationships using a series of Cox proportional hazards models, including adjusting for
demographics alone (age, sex, race)as well as additional adjustment for the more
comprehensive set of predictors (“final clinical model”) that were identified in the
adjustment model developed for the overall HF-ACTION cohort for each endpoint as
previously described16.(see Appendix for a list of covariates). For the relationship between
baseline ST2 and change in peak VO2 at 3 months, inverse probability weighting was used
to adjust for missingness of exercise parameters during follow-up (16% of patients with
available ST2 data were missing peak VO2 at 3 months). The relationship between ST2 at
baseline and change peak VO2 at 3 months was then analyzed using a linear regression
model that included change in peak VO2 at 3 months (transformed to achieve normality) as
the response variable and ST2 (log 2 ST2) along with potential confounders as explanatory
variables.
Although NT-proBNP was not part of the modeling process for the overall HF-ACTION
study because it was not available in the entire cohort, we additionally examined each model
with and without NT-proBNP, given its known strong association with outcomes in chronic
heart failure17. Because the final adjustment model from the overall HF-ACTION dataset
included variables from CPX testing, which is not routinely available in some clinical
settings, we examined each adjusted model with and without CPX variables.
We examined ST2’s added value to existing models by comparing model discrimination and
risk prediction between models with and without log 2 ST2. The specific measures that we
considered were the C statistic, the integrated discrimination improvement (IDI), and the net
reclassification improvement (NRI). For each model comparison, the summary measures
were reported along with 95% bootstrap confidence intervals based on 100 replications. We
calculated NRI using the Kaplan-Meier estimates of event probabilities at the end of study
follow-up. Because there are no widely accepted categories for the absolute risk of HF, we
calculated the NRI without categories.
Finally, to further explore the potential relationship between NT-proBNP and ST2, we
evaluated the risk in 4 groups defined by dichotomizing each variable (ST2 as above or
below 35 ng/mL cutpoint and NT-proBNP at the median = 857 ng/ml). A p-value ≤0.05 was
considered statistically significant for all analyses. All analyses were completed using SAS
9.2 (Cary, NC).
Results
Evaluable baseline plasma samples were available for 910 patients. Baseline characteristics
for the entire HF-ACTION cohort and the subset with ST2 data available, further stratified
by ST2 above and below 35 ng/mL, are shown in Table 1. The median age of the study
cohort was 59 years; 64% were white, and 71% were male. The median NT-proBNP level
was 857 pg/mL, median LVEF was 24%, and median serum creatinine was 1.2 mg/dL.
Utilization of guideline-based medical therapy for systolic heart failure was high, with 95%
receiving beta-blockers and 74% receiving angiotensin-converting enzyme (ACE) inhibitors.
The subset of patients with available plasma samples for analysis (n=910) was broadly
similar to the HF-ACTION cohort as a whole (n=2331, see Table 1), except that the
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biomarker substudy was limited to patients enrolled in North America. The median ST2
level was 23.7 ng/mL (IQR, 18.6–31.8), and 19.6% (n=179 of 910) of patients had ST2
levels above the proposed prognostic cutpoint of 35 ng/mL. Patients with elevated ST2
levels were more likely to be men and to have markers of more advanced disease, including
higher NYHA class, higher NT-proBNP, and worse renal function (p<0.001 for all).
ST2, functional capacity, and quality of life
We assessed the relationships between ST2 and physician-assessed functional capacity
(NYHA class), objective measures of maximal functional capacity (maximal oxygen
consumption [peak VO2]) and submaximal functional capacity (6-minute walk distance),
and patient-reported quality of life (Kansas City Cardiomyopathy Questionnaire [KCCQ]
summary score). ST2 levels progressively increased with worsening NYHA class (Figure 1).
In general, higher log ST2 levels were significantly but modestly correlated with poorer
baseline functional capacity, including peak VO2 on CPX testing (r= −0.30; p<0.001)and 6-
minute walk distance (r= −0.22; p<0.001). Higher levels of ST2 were modestly associated
with lower quality of life summary scores for the KCCQ (r = 0.15; p<0.001). When ST2 was
considered as a dichotomous variable, an ST2 level >35 ng/mL was associated with
significantly worse peak VO2, CPX exercise duration, and 6-minute walk distance (p<0.001
for all).
ST2 and long-term outcomes
The study cohort was followed for 32 months, during which the raw events rates were 171
deaths (19%), 646 all-cause deaths or hospitalizations (71%), and 312 cardiovascular deaths
or heart failure hospitalizations (34%). In univariable analysis, ST2 was a significantly
associated with all 3 long-term outcomes. Specifically, doubling of the baseline ST2 level
was associated with a significantly increased risk of all-cause death or hospitalization (HR,
1.48; p<0.0001), cardiovascular death or heart failure hospitalization (HR, 2.14; p<0.0001),
and all-cause mortality (HR, 2.33; p<0.0001) (Figure 2). When considered along with NT-
proBNP as 4 groups based on NT-proBNP levels above or below the median and ST2 levels
above or below the 35 ng/mL cutpoint, patients with both markers elevated had a 5.6-fold
increased risk of death during the course of long-term follow up compared to those with
neither marker elevated. (Figure 3). There was no statistical interaction between ST2 and
NTproBNP (p = 0.44).
To adjust for how other covariates may affect the association between ST2 and outcome, we
constructed a series of multivariable models (Table 2). Models were progressively adjusted
for demographics alone, demographics + clinical variables, and demographics + clinical
variables + CPX variables. Finally, each step was assessed with and without the inclusion of
NT-proBNP. For each endpoint, ST2 remained independently associated with long-term
outcomes after adjusting for demographics and NT-proBNP. For the endpoint of
cardiovascular death + heart failure hospitalization, ST2 remained statistically
associated(adjusted HR, 1.32 per doubling of ST2; p=0.0129) even after adjusting for
demographics, NT-proBNP, and clinical and CPX variables. For all-cause mortality, the
final adjusted HR was similar (1.26), though it did not reach nominal statistical significance
(p=0.0877). ST2 was not significantly associated with the composite of all-cause mortality +
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rehospitalization (adjusted HR, 1.08; p=0.3605) after final adjustment for demographics,
NT-proBNP, and the final clinical model, including CPX variables.
Because CPX testing is infrequently used or is unavailable at some centers, we examined the
predictive value of ST2 when adjusted for clinical variables and NT-proBNP but excluded
CPX variables (peak V02, exercise duration, and VE-VCO2 slope). In this analysis, ST2 was
significantly associated with all-cause mortality (adjusted HR, 1.42; p=0.0067) and
cardiovascular death or heart failure hospitalization (adjusted HR, 1.37; p=0.0037), but it
was not with all-cause mortality or hospitalization (adjusted HR, 1.13; p=0.1213). To
evaluate the incremental value of ST2, we examined several measures of model
performance, including the change in the C statistic, IDI and category free NRI. The
addition of ST2 did not substantially change the C-statistic, IDI, or NRI for any of the
clinical endpoints (Table 3). This suggests that while ST2 is significantly associated with
outcomes, adding ST2 to models containing the clinical risk factors and NT-proBNP does
not incrementally improve discrimination or risk prediction.
ST2 and response to exercise training
Given that HF-ACTION was a randomized, controlled study of a unique intervention
(exercise training), we tested for an interaction between baseline ST2 levels and the
treatment effect of exercise training with regard to each of the clinical outcomes of interest.
Of the endpoints tested, there was a statistical interaction between exercise training and the
outcome of all-cause mortality, such that patients with lower ST2 levels were more likely to
have a benefit of exercise training than were patients with higher levels (p=0.016 for ST2 *
treatment interaction), and a similar interaction for cardiovascular mortality (p = 0.032 for
ST2* treatment interaction). There was not a similar statistical interaction between ST2
levels and treatment effects with regard to the composite endpoints of all-cause death or
hospitalization (p=0.620) or cardiovascular death or heart failure hospitalization (p=0.224).
We also assessed the relationship between baseline ST2 levels and the change in peak VO2
between baseline and 3 months. Higher baseline ST2 levels were associated with a greater
training effect (i.e., the increase in peak VO2 from baseline to 3 months (adjusted p value =
0.034)). There was no significant interaction between baseline ST2 levels and treatment
assignment(exercise vs. control) (Figure 4).
Discussion
Soluble ST2 is a novel biomarker that reflects a variety of important pathologic processes in
heart failure, including myocyte stretch and inflammation. ST2/IL-33 signaling is induced
by myocyte stretch and modulates hypertrophic responses and fibrosis in the myocardium18.
Intact ST2/IL-33 signaling is believed to be a mechanically activated cardioprotective
paracrine signaling system that shields the myocardium from the adverse effects of overload.
Because ST2 elevations reflect activation of distinct biologic systems compared with the
natriuretic peptides, there is significant interest in whether ST2 can add additional
prognostic information. In this analysis of the HF-ACTION study, ST2 was significantly
associated with long-term outcome even after a adjustment for clinical covariates. Addition
of NT-proBNP attenuated the association with the primary outcome of all-cause death and
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hospitalizations. To our knowledge, this is the most robust test of this novel biomarker to
date with regard to covariate adjustment in a large, multicenter cohort of ambulatory heart
failure patients. Although the association between ST2 and outcomes was consistent across
all outcomes, the addition of ST2 to a model adjusted for known risk factors did not lead to
improved discrimination and risk prediction based on reclassification analysis. The overall
effect sizes were modest (all adjusted HR were < 1.5 per doubling of ST2). These data
demonstrate the limitations of multivariable modeling alone as an assessment of the clinical
value of new biomarkers.
We believe these findings are of interest for several reasons. To our knowledge, this is the
first study to have comprehensively examined the relationship between ST2, commonly
used measures of functional capacity, and response to exercise training in heart failure
patients. We found that ST2 levels were significantly associated with both physician
assessed (NYHA class) and objective measures of functional capacity (6-minute walk
distance and peak VO2). Additionally, baseline levels of ST2 were predictive of training
effect (the change in peak VO2 over 3 months). We also identified an interaction between
ST2 levels and exercise training, such that patients with lower ST2 levels were more likely
to have beneficial effects of exercise training with regard to the endpoint of all-cause
mortality. We did not observe a similar interaction for the composite endpoints, and it is
uncertain whether this observation represents a true effect or is a due to chance. Prior data
have suggested a relationship between extracellular matrix turnover and changes in exercise
capacity over time19. Weir et al showed that high ST2 levels are associated with greater
response to eplerenone therapy after acute myocardial infarction20. Recent data regarding
galectin-3, another marker thought to reflect myocardial fibrosis and remodeling, have
suggested a similar differential effect (greater efficacy of statin therapy in patients with
lower levels of the biomarker)21. Further analyses in other randomized trial datasets will be
needed to confirm or refute this initial signal regarding the interaction between ST2 levels
and treatment response in heart failure.
Our study extends the results of other studies that have examined the relationship between
ST2 and outcomes in chronic heart failure4, 22, 23. Most notably, our data complement the
previous analysis from Ky et al from the Penn Heart Failure Study (PHFS), which showed
an association between ST2 levels and outcomes in an observational cohort from 3 tertiary
care referral centers4. In comparison, our study cohort was more broadly representative of
the systolic heart failure population because we included both a variety of academic- and
community-based clinical sites and had a more representative proportion of patients with
ischemic etiology (51% for HF-ACTION vs. 31% for PHFS). Additionally, our study had
blinded independent adjudication of clinical outcomes, allowing for the robust distinction
between disease-specific and all-cause endpoints. We found that the relationship between
ST2 and outcomes may be stronger for disease-specific outcomes (such as HF
hospitalization and CV morality) compared with all-cause outcomes. HF-ACTION routinely
collected detailed data on functional capacity using CPX testing and 6-minute walk distance,
allowing for both an assessment of the relationship between ST2 and functional capacity as
well as more detailed covariate adjustment in multivariable models. Finally, because HF-
ACTION was an intervention study, we were able to assess interactions between the
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intervention of exercise training (which has putative immunomodulatory effects)24 and ST2
levels with regard to outcomes.
Limitations
The study population for this analysis was derived from the HF-ACTION study, and as
such, is susceptible to the limitations inherent in clinical trial populations. Although more
broadly generalizable than other cohorts in which ST2 has been examined, our population
was still relatively young (median age 59) compared with the broader heart failure
population. HF-ACTION was a randomized study and the study intervention (exercise
training) did demonstrate a treatment effect, a fact that may have potentially influenced our
results and could limit the generalizability to other settings. Our study population consisted
only of patients with impaired ejection fraction (LVEF <0.35), so our results cannot be
extrapolated to the population of patients with heart failure and preserved ejection fraction.
Conclusions
In this analysis of a large clinical study cohort of well-treated ambulatory heart failure
patients, elevation of ST2 was significantly associated with long-term outcomes, especially
disease-specific outcomes. These associations were relatively robust for disease specific
endpoints (cardiovascular death and heart failure hospitalization) in traditional multivariable
modeling, persisting even after comprehensive covariate adjustment, including
demographics, clinical variables, and NT-proBNP. Despite this robust relationship in
traditional multivariable modeling, ST2 did not add significantly to discrimination or risk
prediction. Ongoing research will further clarify the role of ST2 in risk stratification in
chronic heart failure.
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NT-proBNP amino-terminal pro–B-type natriuretic peptide
NYHA New York Heart Association
Peak VO2 maximal oxygen consumption
Felker et al. Page 8























1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford
ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ,
Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy
CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N,
Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics—2012
update: A report from the american heart association. Circulation. 2012; 125:e2–e220. [PubMed:
22179539]
2. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ.
Trends in heart failure incidence and survival in a community-based population. Jama. 2004;
292:344–350. [PubMed: 15265849]
3. Braunwald E. Biomarkers in heart failure. New England Journal of Medicine. 2008; 358:2148–
2159. [PubMed: 18480207]
4. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries DL, Tang WHW, Wu AHB,
Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola TP. High-sensitivity
st2 for prediction of adverse outcomes in chronic heart failure / clinical perspective. Circulation:
Heart Failure. 2011; 4:180–187. [PubMed: 21178018]
5. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M,
Kitzman DW, Zannad F, Pina IL, O’Connor CM. Galectin-3 in ambulatory patients with heart
failure: Results from the hf-action study. Circ Heart Fail. 2012; 5:72–78. [PubMed: 22016505]
6. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler
H, Wollert KC. Serial measurement of growth-differentiation factor-15 in heart failure / clinical
perspective. Circulation. 2010; 122:1387–1395. [PubMed: 20855664]
7. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C,
Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand IS, Ng L, Daniels LB, Neath
SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von
Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Increased 90-day mortality in patients with
acute heart failure with elevated copeptin: Secondary results from the biomarkers in acute heart
failure (bach) study. Circ Heart Fail. 2011; 4:613–620. [PubMed: 21765124]
8. Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH,
Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX,
Christenson R, Potocki M, McCord J, Hartmann O, Morgenthaler NG, Anker SD. Midregion
prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea results from
the bach (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2011; 58:1057–1067.
[PubMed: 21867843]
9. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33
prevents apoptosis and improves survival after experimental myocardial infarction through st2
signaling. Circ Heart Fail. 2009; 2:684–691. [PubMed: 19919994]
10. Miller AM, Liew FY. The il-33/st2 pathway - a new therapeutic target in cardiovascular disease.
Pharmacol Ther. 2011; 131:179–186. [PubMed: 21356240]
11. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP,
Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain st2 and n-
terminal prohormone b-type natriuretic peptide in patients with st-elevation myocardial infarction.
Circulation. 2008; 117:1936–1944. [PubMed: 18378613]
12. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O’Donoghue M, Sakhuja
R, Chen AA, van Kimmenade RRJ, Lewandrowski KB, Lloyd-Jones DM, Wu AHB. Measurement
of the interleukin family member st2 in patients with acute dyspnea: Results from the pride (pro-
brain natriuretic peptide investigation of dyspnea in the emergency department) study. J Am Coll
Cardiol. 2007; 50:607–613. [PubMed: 17692745]
13. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE,
Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS,
Zannad F, Pina IL. Efficacy and safety of exercise training in patients with chronic heart failure:
Hf-action randomized controlled trial. Jama. 2009; 301:1439–1450. [PubMed: 19351941]
Felker et al. Page 9






















14. Whellan DJ, O’Connor CM, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE,
Kitzman DW, Blumenthal JA, Rendall DS, Houston-Miller N, Fleg JL, Schulman KA, Pina IL.
Heart failure and a controlled trial investigating outcomes of exercise training (hf-action): Design
and rationale. Am Heart J. 2007; 153:201–211. [PubMed: 17239677]
15. Lu J, Snider JV, Grenache DG. Establishment of reference intervals for soluble st2 from a united
states population. Clin Chim Acta. 2010; 411:1825–1826. [PubMed: 20654603]
16. O’Connor CM, Whellan DJ, Wojdyla D, Leifer E, Clare RM, Ellis SJ, Fine LJ, Fleg JL, Zannad F,
Keteyian SJ, Kitzman DW, Kraus WE, Rendall D, Pina IL, Cooper LS, Fiuzat M, Lee KL. Factors
related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction:
The hf-action predictive risk score model. Circ Heart Fail. 2012; 5:63–71. [PubMed: 22114101]
17. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G,
Cohn JN. on behalf of the Val-HeFT Investigators. Direct comparison of b-type natriuretic peptide
(bnp) and amino-terminal probnp in a large population of patients with chronic and symptomatic
heart failure: The valsartan heart failure (val-heft) data. Clin Chem. 2006; 52:1528–1538.
[PubMed: 16777915]
18. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. Il-33 and st2 comprise a
critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;
117:1538–1549. [PubMed: 17492053]
19. Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ,
Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F. Extracellular matrix
turnover and inflammatory markers independently predict functional status and outcome in
chronic heart failure. J Card Fail. 2008; 14:467–474. [PubMed: 18672194]
20. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ,
McMurray JJ. Serum soluble st2: A potential novel mediator in left ventricular and infarct
remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55:243–250. [PubMed:
20117403]
21. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, Adourian A, Bohm M, van
Veldhuisen DJ, Komajda M, Cleland JG, Wikstrand J, McMurray JJ, Aukrust P. Galectin-3
predicts response to statin therapy in the controlled rosuvastatin multinational trial in heart failure
(corona). Eur Heart J. 2012; 33:2290–2296. [PubMed: 22513778]
22. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, Cinca J, de Luna
AB, Bayes-Genis A. Soluble st2 for predicting sudden cardiac death in patients with chronic heart
failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009; 54:2174–2179.
[PubMed: 19942089]
23. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum
soluble st2 receptor as a novel heart failure biomarker. Circulation. 2003; 107:721–726. [PubMed:
12578875]
24. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among
apparently healthy middle age and older us adults. Arch Intern Med. 2002; 162:1286–1292.
[PubMed: 12038947]
Appendix
Final covariates used in adjusted models for each endpoint:
All-cause death or all-cause hospitalization (primary endpoint): peak VO2 (as Weber class),
sex, region (United States vs. non-United States), mitral regurgitation severity, ventricular
conduction on electrocardiogram, blood urea nitrogen, ejection fraction, beta-blocker dose
(truncated at 50 mg/day carvedilol equivalent), and Kansas City Cardiomyopathy
Questionnaire symptom stability score.
Cardiovascular death or heart failure hospitalization: sex, race, age (truncated above 62
years), loop diuretic dose (using furosemide equivalent, truncated above 100 mg/day), left
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ventricular ejection fraction, mitral regurgitation severity, blood urea nitrogen (truncated
above 39 mg/dL), VE/VC02 slope (truncated above 80), Kansas City Cardiomyopathy
Questionnaire symptom stability score, ventricular conduction on electrocardiogram,
baseline maximal oxygen consumption, truncated above 28 mL/kg/min.
All-cause mortality:sex, body mass index (truncated above 25), loop diuretic dose (truncated
above 100mg furosemide daily), Canadian Angina Class, ventricular conduction on
electrocardiogram, left ventricular ejection fraction, exercise duration on cardiopulmonary
exercise test, serum creatinine (truncated above 2.3).
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Median ST2 levels by NYHA class. Error bars represent intraquartile range.
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Kaplan Meier plost for ST2 above or below 35 ng/mL for (A) All cause mortality, (B) all-
cause mortality+ all cause hospitalization, and C) CV death + Heart failure hospitalization
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Hazard for all-cause mortality based on groups defined by NT-proBNP (above or below
median of 857 pg/mL) and ST2 (above or below 35 ng/mL), compared with a reference
group with low NT-proBNP and low ST2. P values are for change relative to reference
group. Interaction between NTproBNP and ST2 was not signficant (p = 0.44).
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Mean change from baseline to 3 months in peak VO2 stratfied by treatment assignment and
ST2 levels. Baseline ST2 level was siginficant predictor of change in peak VO2 (adjusted p
= 0.034). There was no signficant interaction between treatment assignment and ST2 levels
with regard to predicting improvement in peak V02 (p = 0.67 for treatment*ST2
interaction). Error bars represent standard deviations.
Felker et al. Page 16







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Circ Heart Fail. Author manuscript; available in PMC 2014 October 07.
